Loading...
Market
How many FluMist nasal spray doses will be sold through third-party pharmacies in Q4 2024?
2
Resolution / Starting Odds
1 to 2 million • 25%
Less than 1 million • 25%
2 to 3 million • 25%
More than 3 million • 25%
Sales reports from AstraZeneca or major pharmacy chains
Story
FDA Approves First Self-Administered FluMist Nasal Spray for At-Home Use
Sep 20, 2024, 08:03 PM
The U.S. Food and Drug Administration (FDA) has approved AstraZeneca's FluMist nasal spray influenza vaccine for self- or caregiver-administration. This approval marks the first time a flu vaccine can be administered at home without the need for a healthcare provider. FluMist is licensed for individuals between the ages of 2 and 49 and is designed to prevent influenza caused by virus subtypes A and B. The vaccine, which contains a weakened live virus, will be available through third-party pharmacies, where individuals will complete a screening and eligibility assessment when ordering. This move is part of a broader effort by the FDA to expand consumer access to medicines and reduce costs and barriers to care.
View original story
Similar markets
Less than 1,000 • 25%
1,000-2,000 • 25%
2,000-3,000 • 25%
More than 3,000 • 25%
Less than 500,000 • 25%
500,000 to 1 million • 25%
1 million to 2 million • 25%
More than 2 million • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
CVS • 25%
Walgreens • 25%
Rite Aid • 25%
Other • 25%
Yes • 50%
No • 50%
Less than 5% • 25%
5% to 10% • 25%
10% to 20% • 25%
More than 20% • 25%
Pharmacies • 25%
Online retailers • 25%
Healthcare providers • 25%
Other • 25%
Less than 5% • 25%
5-10% • 25%
10-20% • 25%
More than 20% • 25%